Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Morneau, Mélanie; Foster, William; Lalancette, Marc; Nguyen-Huynh, Thu Van; Renaud, Marie-Claude; Samouëlian, Vanessa; Letarte, Nathalie; Almanric, Karine; Boily, Gino; Bouchard, Philippe; Cournoyer, Ghislain; Couture, Félix; Gervais, Normand; Goulet, Stéphanie; Guay, Marie‐Claude; Kavanagh, Mélanie; Lemieux, Julie; Bernard, Loris; Ouellet, Jean-François; Pineau, Gilles; Rajan, Raghu; Roy, Isabelle; Samson, Benoît; Sidéris, Lucas; Vincent, François

doi:10.1016/j.ygyno.2013.07.084

Cited by 18 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients also received postoperative therapy, as was the standard treatment at the time. The benefit of such treatment has since been re-evaluated and it is currently not recommended for low-risk patients (29). The effects of the treatment on patient survival have likely been minimal, thus not affecting the integrity of the study.…”

Section: Resultsmentioning

confidence: 99%

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Santala

Talvensaari-Mattila

Soini

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Santala

Talvensaari-Mattila

Soini

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Several recent studies have shown that patients with EC have specific recurrence patterns according to their ESMO-ESGO-ESTRO group of risk [591011]. In their study, Bendifallah et al [11] stated that patterns of recurrence in EC differ widely in terms of localization and timing depending on the risk subgroup.…”

Section: Discussionmentioning

confidence: 99%

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

et al. 2019

View full text Add to dashboard Cite

Objective According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS). Methods Data of 191 patients with IR and HIR EC who underwent primary surgery with or without VB and no other adjuvant treatment between 2000 and 2016 were extracted from the FRANCOGYN database. Rate of local recurrence, OS and local RFS in these two groups were compared using the Kaplan-Meier method. Results The number of patients with IR and HIR EC were 118 and 73 respectively. VB was used in 92 patients in IR group and 43 in HIR group. Median follow-up was 22 months. In the HIR group, the local recurrence rate was significantly higher in the no adjuvant therapy group in comparison with the VB group (16.7% and 0% respectively, p=0.02). There was also a significant improvement in local RFS (p=0.01) in VB group. In IR EC, there is no significant difference on local recurrence rate (4.2% and 3.2%, respectively, p=1.00) or local RFS (p=0.54) between the two groups. Conclusions VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.

show abstract

“…For women with high-risk early-stage (endometrioid adenocarcinoma stage IB grade 3 or stage II endometrioid and any stage nonendometrioid histologies) or locally advanced disease (stages III to IVA), pelvic radiotherapy is usually recommended, despite the fact that there is no high-level evidence to support it. 10 , 12 …”

Section: Discussionmentioning

confidence: 99%

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Bonadio

Azevedo

Harada

et al. 2018

JGO

View full text Add to dashboard Cite

PurposeThe best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy.Patients and MethodsWe performed a retrospective analysis of patients with high-risk endometrial cancer (endometrioid histology stages III to IVA or carcinosarcoma, clear cell, or serous histology stages I to IVA) treated with adjuvant carboplatin and paclitaxel, followed by radiotherapy, from 2010 to 2017 at a Brazilian cancer center. The Kaplan-Meier method was used for survival analysis, and prognostic factors were analyzed using the Cox proportional hazards model.ResultsOne hundred forty-six consecutive patients were evaluated. The OS rates were 86.2% at 3 years and 75.4% at 5 years. OS was significantly affected by pelvic lymphadenectomy (P = .001) and positive peritoneal cytology (P < .001). Three- and 5-year disease-free survival (DFS) rates were 78.3% and 69.5%, respectively. The initial site of recurrence was limited to the pelvis in 4.1% of patients, within the abdomen in 1.3%, and extra-abdominal in 11.6%. Patients with grade 1 or 2 endometrioid carcinoma had better prognosis than patients with endometrioid carcinoma grade 3 or nonendometrioid histology (3-year DFS, 93.67% v 68.5%, respectively; P = .0017).ConclusionAdjuvant carboplatin and paclitaxel, followed by radiotherapy, is effective in high-risk endometrial cancer and associated with low rates of pelvic recurrence, which might be explained by the addition of radiotherapy. The high-risk group is heterogeneous, and the benefit of adjuvant treatment in patients with grade 1 or 2 endometrioid carcinoma is less clear.

show abstract

Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Cited by 18 publications

References 48 publications

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Contact Info

Product

Resources

About